Valbiotis announces positive results for Cardio-Liver and launches ValbiotisPRO® Liver

Valbiotis has unveiled the positive results of the Cardio-Liver clinical study. The research shows that Steadrive®, the active formula, reduces liver fat and improves various metabolic parameters. The study, conducted on 71 volunteers, is a significant advancement for the ValbiotisPRO® product line.

The launch of ValbiotisPRO® Liver, scheduled for September 23, marks the end of the clinical development program. In France, where overweight affects nearly half of adults, this supplement offers a natural and scientifically validated solution to alleviate metabolic imbalances.

Available in pharmacies and online, it relies on a multi-channel marketing strategy. This launch expands the range of products dedicated to cardiometabolic health, based on rigorous clinical research.